From 2012 to 2022, the insulin dosage market size per capita in Japan saw a significant decline. Starting at 26.95 percent USD per capita in 2012, the value reduced over the years, reaching 14 in 2022. This represents a compound annual growth rate (CAGR) of approximately -6.1% over the last five years (2018-2022).
Year-on-year variations indicate a generally downward trend, with minor fluctuations around 2020-2021. Specifically, the market size per capita decreased from 15.09 in 2019 to 16.07 in 2020 and slightly increased to 16.22 in 2021 before dropping to 14 in 2022. This decrease underscores a consistent downward trajectory resumed after minor rises.
Future trends to watch for: - Potential stabilization or further decline in market size per capita. - Influence of new technologies and treatments on market demand. - Regulatory changes impacting supply and pricing. - Trends in diabetes prevalence and healthcare policies in Japan.
| # | 22 Countries | US Dollars Per Capita | Last Year | |||
|---|---|---|---|---|---|---|
| 1 | 1 Germany | 29.7 | 2023 | View data | ||
| 2 | 2 United Kingdom | 27.44 | 2023 | View data | ||
| 3 | 3 Greece | 26.06 | 2023 | View data | ||
| 4 | 4 Netherlands | 24.72 | 2023 | View data | ||
| 5 | 5 Belgium | 21.98 | 2023 | View data | ||
| 12 | 12 Slovenia | 16.43 | 2023 | View data | ||
| 13 | 13 Slovakia | 13.6 | 2023 | View data | ||
| 14 | 14 Japan | 13.48 | 2023 | |||
| 15 | 15 Lithuania | 12.65 | 2023 | View data | ||
| 16 | 16 Ireland | 11.52 | 2023 | View data | ||
